Sig Kirk and his team have completed more than 50 transactions at Allergan, including acquisitions, licensing agreements and development collaborations. He has played an instrumental role in Allergan’s largest acquisitions, including Warner Chilcott ($8.5 Billion), Forest Laboratories ($30.9 Billion) and the predecessor Allergan ($70.5 Billion). In addition, Sig helped lead the $40 Billion sale of the global generics business to Teva Pharmaceuticals. He previously served as Vice President of Watson, joining the company in 2009. Before joining Watson, Mr. Kirk served as Senior Vice President, Global Controller and Chief Accounting Officer of Barr Pharmaceuticals, prior to its acquisition by Teva.
Executive Vice President, Corporate Business Development
For questions or additional information, please contact Rachel Gisser at firstname.lastname@example.org.